Interim data from Roche Group member Genentech’s first randomized study of a candidate treatment for extensive-stage small cell lung cancer (ES-SCLC) failed to meet the clinical trial’s co-primary endpoint against the hard-to-treat disease.
Pardes Biosciences Inc. said on February 14 the company expects to start a mid-to-late-stage trial of its experimental COVID-19 antiviral pill by mid-2022, following promising data from early human testing.
At WORLDSymposium, Astellas Pharma presented interim safety data from a Phase I/II study assessing the company’s AAV gene therapy for the rare, autosomal metabolic disease Pompe disease.
Shares of Taysha Gene Therapies were down more than 10 percent after a patient’s death marred positive interim data for the company’s experimental gene therapy treatment for Sandhoff and Tay-Sachs diseases, which are two forms of GM2 gangliosidosis.
Merck has submitted data to the U.S. Food and Drug Administration for Emergency Use Authorization (EUA) for the company’s antiviral pill molnupiravir.
Sanofi said on Oct. 6 that the French healthcare company had found positive results from the first study into a high-dose influenza vaccine with a Covid-19 mRNA booster.
Early data from a Phase III study of Brii Biosciences’ monoclonal antibody combination therapy for Covid-19 is showing significant promise.
A booster dose of Johnson & Johnson’s Covid-19 vaccine sharply increased levels of antibodies against the coronavirus, according to interim data from two small, early-stage trials, the company said in a press release on Aug. 25.
An antiviral treatment under development by Atea Pharmaceuticals is showing promise against Covid-19.
The European Union’s drug regulator said on May 21 a Covid-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology can be used to treat patients who are at risk of severe disease and do not need supplemental oxygen.
